We recently compiled a list of the 10 Firms Lead Thursday’s Rally on Better Earnings, Bargain-Hunting. In this article, we ...
We recently compiled a list of the 12 Stocks That Will Double in 2025. In this article, we are going to take a look at where ...
ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click ...
CULVER CITY, Calif., January 29, 2025--ImmunityBio, Inc. (NASDAQ: IBRX) today announced it has entered into a collaboration and supply agreement with BeiGene, Ltd. (to be changed to BeOne ...
Mutual Advisors LLC bought a new position in ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).
ImmunityBio, Inc. (NASDAQ:IBRX) saw a surge in its share prices last week, closing higher by 21.49 percent at $2.94 apiece as ...
ImmunityBio has a promising cancer treatment, Anktiva. We warn of financial risks and lack of transparency for retail investors. See more on IBRX stock here.
1 Day IBRX 1.60% DJIA -0.32% S&P Mid Cap 400 -0.08% Health Care/Life Sciences -0.52% ...
ImmunityBio (IBRX) announced the European Medicines Agency has accepted for review and begun assessing the marketing authorization application ...
We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where Immunitybio, Inc. (NASDAQ:IBRX) stands against other firms that took a hit on ...
CULVER CITY, Calif., January 27, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the European Medicines Agency (EMA) has accepted for review and begun ...